Key result
Patients with postural orthostatic tachycardia syndrome had higher plasma levels of growth hormone (9.37 vs 8.37 NPX) and lower levels of myoglobin (4.86 vs 5.14 NPX) compared to controls.
Why the study?
Postural orthostatic tachycardia syndrome is a cardiovascular autonomic disorder of unknown etiology, motivating the identification of novel cardiovascular biomarkers potentially implicated in its pathophysiology.
Does targeted cardiovascular proteomics identify novel biomarkers associated with postural orthostatic tachycardia syndrome (POTS) compared to normal hemodynamic response?
Case-Control (n=396)
No
Does targeted cardiovascular proteomics identify novel biomarkers associated with postural orthostatic tachycardia syndrome (POTS) compared to normal hemodynamic response?
Absolute Event Rate: 9.37% vs 8.37%
p-value: p=0.002
Proteomic analysis reveals a sex-specific biomarker signature in POTS, characterized by higher growth hormone in women and lower myoglobin in men, suggesting potential immune-neuroendocrine dysregulation and deconditioning.
May support neuroendocrine dysregulation in POTS; hypothesis-generating for biomarker validation in prospective studies.
BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is a variant of cardiovascular (CV) autonomic disorder of unknown etiology characterized by an excessive heart rate increase on standing and orthostatic intolerance. In this study we sought to identify novel CV biomarkers potentially implicated in POTS pathophysiology. METHODS: We conducted a nested case-control study within the Syncope Study of Unselected Population in Malmö (SYSTEMA) cohort including 396 patients (age range, 15-50 years) with either POTS (n = 113) or normal hemodynamic response during passive head-up-tilt test (n = 283). We used a targeted approach to explore changes in cardiovascular proteomics associated with POTS through a sequential two-stage process including supervised principal component analysis and univariate ANOVA with Bonferroni correction. RESULTS: POTS patients were younger (26 vs. 31 years; p < 0.001) and had lower BMI than controls. The discovery algorithm identified growth hormone (GH) and myoglobin (MB) as the most specific biomarker fingerprint for POTS. Plasma level of GH was higher (9.37 vs 8.37 of normalised protein expression units (NPX); p = 0.002), whereas MB was lower (4.86 vs 5.14 NPX; p = 0.002) in POTS compared with controls. In multivariate regression analysis, adjusted for age and BMI, and stratified by sex, lower MB level in men and higher GH level in women remained independently associated with POTS. CONCLUSIONS: Cardiovascular proteomics analysis revealed sex-specific biomarker signature in POTS featured by higher plasma level of GH in women and lower plasma level of MB in men. These findings point to sex-specific immune-neuroendocrine dysregulation and deconditioning as potentially key pathophysiological traits underlying POTS.
No takes yet. Share an insight, caveat, or question.
Spahic et al. (2020) conducted a case-control in Postural orthostatic tachycardia syndrome (n=396). Postural orthostatic tachycardia syndrome vs. Normal hemodynamic response was evaluated on Plasma level of growth hormone (GH) in normalised protein expression units (NPX) (p=0.002). Patients with postural orthostatic tachycardia syndrome had higher plasma levels of growth hormone (9.37 vs 8.37 NPX) and lower levels of myoglobin (4.86 vs 5.14 NPX) compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: